News | Radiopharmaceuticals and Tracers | February 14, 2024

Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients

Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients

Getty Images

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, today announces the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac) starting in the second half of 2024.

This first agreement with a major drug developer reflects PanTera’s unique position to be a reliable, EU-based supplier of 225Ac from this year onward. In 2024, PanTera will continue to work on increasing access to 225Ac for clinical trial needs, as well as on the development of a large-scale, state-of-the-art production facility to address growing global demand.

Sven Van den Berghe, CEO of PanTera, commented, “PanTera’s emerging ability to start supplying 225Ac this year will allow research and clinical trials in this domain to advance. The combined expertise and technology from SCK CEN and IBA places PanTera in a unique position to become the go-to global supplier of 225Ac for clinical trials and commercial use. PanTera is committed to supporting the pharmaceutical industry by scaling up production to meet the significant global demand for targeted radiopharma-based therapeutics in the fight against cancer.”

For more information:


Related content:

IBA Pioneers Theranostic Advancements, Empowering the Market to Produce Astatine-211

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma  

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones     

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)       

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)         

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal         

Update on Unplanned Outage of the HFR Reactor         

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply         

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals         

How Nuclear Fusion is Revolutionizing Medical Isotope Production         

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes         

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE         

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
News | Radiology Business

January 23, 2024 — Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals ...

Time January 23, 2024
Subscribe Now